42.57

2.09% 0.86

Xenon Pharmaceuticals Inc (XENE)

Overview News Price History Option Chain Financials Discussions Forecast

Xenon Pharmaceuticals Inc stock is traded at $42.57, with a volume of 78,741. It is up +2.09% in the last 24 hours and up +4.54% over the past month. Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Previous Close:

$41.71

Open:

$41.52

24h Volume:

78,741

Relative Volume:

0.25

Market Cap:

$3.22B

Revenue:

$13.17M

Net Income/Loss:

$-199.06M

P/E Ratio:

-17.10

EPS:

-2.49

Net Cash Flow:

$-156.53M

1W Performance:

+1.92%

1M Performance:

+4.54%

6M Performance:

-2.67%

1Y Performance:

+29.50%

1-Day Range:

$41.52

$42.67

1-Week Range:

$40.66

$42.67

52-Week Range:

$27.98

$50.99

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Name

Xenon Pharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(604) 484-3300

Address

200 - 3650 GILMORE WAY, BURNABY

Employee

259

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

XENE's Discussions on Twitter

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-24	Resumed	Raymond James	Outperform
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jan-04-24	Initiated	Citigroup	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Apr-25-23	Initiated	Cantor Fitzgerald	Overweight
Dec-14-22	Initiated	Goldman	Buy
Dec-12-22	Initiated	Cowen	Outperform
Nov-28-22	Initiated	Wells Fargo	Overweight
Oct-19-22	Initiated	Raymond James	Outperform
Aug-29-22	Initiated	BofA Securities	Buy
Jul-21-22	Initiated	JP Morgan	Overweight
Oct-28-21	Initiated	RBC Capital Mkts	Outperform
Oct-02-20	Initiated	SVB Leerink	Outperform
Jul-21-20	Initiated	Needham	Buy
Jun-01-20	Resumed	Jefferies	Buy
Mar-25-20	Initiated	Wedbush	Outperform
Jan-08-20	Initiated	William Blair	Outperform
Sep-20-19	Initiated	Guggenheim	Buy
Aug-08-18	Reiterated	Stifel	Buy
Mar-13-17	Initiated	Jefferies	Buy
Oct-21-16	Initiated	Stifel	Buy
Sep-26-16	Initiated	Guggenheim	Buy
Apr-14-16	Reiterated	Jefferies	Buy
Oct-30-15	Resumed	Jefferies	Buy
Dec-02-14	Initiated	Canaccord Genuity	Buy

View All

Xenon Pharmaceuticals Inc Stock (XENE) Latest News

05:22 AM

Harbor Capital Advisors Inc. Buys 23,947 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat

05:22 AM

03:37 AM

Allspring Global Investments Holdings LLC Sells 21,269 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

03:37 AM

Nov 04, 2024

New Horizons in Tonic-clonic Seizure Market Exploring Future - openPR

Nov 04, 2024

Nov 03, 2024

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by abrdn plc - MarketBeat

Nov 03, 2024

Nov 02, 2024

Repligen Co. (NASDAQ:RGEN) Position Boosted by Blue Trust Inc. - Defense World

Nov 02, 2024

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of “Buy” by Brokerages - Defense World

Nov 02, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Creative Planning - Defense World

Nov 02, 2024

Creative Planning Buys 2,475 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World

Nov 02, 2024

Blue Trust Inc. Has $39,000 Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World

Nov 02, 2024

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages - MarketBeat

Nov 02, 2024

Oct 31, 2024

Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat

Oct 31, 2024

Oct 29, 2024

Epilepsy Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR

Oct 29, 2024

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Pass Above 50-Day Moving AverageHere's What Happened - MarketBeat

Oct 29, 2024

Assenagon Asset Management S.A. Acquires 138,685 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat

Oct 29, 2024

Oct 25, 2024

When (XENE) Moves Investors should Listen - Stock Traders Daily

Oct 25, 2024

Oct 20, 2024

SG Americas Securities LLC Sells 18,463 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat

Oct 20, 2024

Oct 18, 2024

Leerink Partnrs Has Negative Outlook of XENE FY2026 Earnings - MarketBeat

Oct 18, 2024

Oct 17, 2024

Stock Traders Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat

Oct 17, 2024

Oct 14, 2024

How To Trade (XENE) - Stock Traders Daily

Oct 14, 2024

Oct 11, 2024

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe - Zacks Investment Research

Oct 11, 2024

Millennium Management LLC Increases Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat

Oct 11, 2024

Oct 10, 2024